Action required: Please refresh your browser
We have recently implemented some changes that require a hard refresh of your browser: Please hold down the CTRL-key and press the F5 key.
After a successful hard refresh, this message should not appear anymore.
More details about this topic are available here »
Intrommune Therapeutics Presents at Next Generation Food Allergy Drug Summit | ||
By: GlobeNewswire - 22 Jul 2021 | Back to overview list |
|
Scientific Data Outlines the Role of the Oral Mucosa in the Delivery of Peanut Allergy Immunotherapy NEW YORK, July 22, 2021 (GLOBE NEWSWIRE) -- Intrommune Therapeutics, a New York-based clinical stage biotechnology company developing a patient-friendly treatment platform for peanut and other food allergies, is participating in the Next Generation Food Allergy Drug Summit. This annual event takes place July 20-22, 2021. William Reisacher, MD and Abhit Singh, MD are participating in the event for Intrommune. William Reisacher, MD, Professor of Otolaryngology and the Director of Allergy Services within the Department of Otolaryngology-Head and Neck Surgery, Weill Cornell Medicine/New York-Presbyterian Hospital, presented the following talk at the conference, “Food 101: Why the Oral Cavity is the Best Classroom for Educating the Immune System.” Dr. Reisacher is also the inventor of oral mucosal immunotherapy (OMIT) and is a Senior Scientific Advisor to Intrommune Therapeutics. “We consider oral mucosal immunotherapy a super-strategy for the management of food allergies,” said Dr. Reisacher. “A toothpaste-based modality delivers allergens to the majority of the oral cavity surface area without the risk of significant ingestion of peanut protein. This optimizes both safety and efficacy, expanding on the successful peanut desensitization proven to occur when liquid peanut protein is repeatedly placed under the tongue, and provides more options for younger children.” Abhit Singh, MD, VP, Medical Affairs, Intrommune, presented a talk entitled, “Highlighting the Regulatory Pathway & Timelines: Working Towards an IND.” Dr. Singh worked on Intrommune’s successful 2020 INT-301 IND submission to the FDA. INT301 is a first-in-class formulation designed to desensitize an individual with peanut allergy using a toothpaste delivery system, ideally protecting them in the event of accidental peanut exposure. “We are very excited about the currently enrolling phase 1B trial of INT301, and we hope to escalate our development program based on results of this study,” said Dr. Singh. “The successful development of INT301 will demonstrate that food allergy immunotherapy can be accurately and effectively dispensed in order to ensure comprehensive patient-safety.” Intrommune is actively enrolling patients in its phase1B clinical trial. More information about this trial can be found here: https://www.circuitclinical.com/trial-details/circuit-wny/138. About Peanut and Other Food Allergies About Oral Mucosal Immunotherapy™ About Intrommune Therapeutics Contact: Cautionary Statement Regarding Forward Looking Statements |
||
|
||
Copyright 2021 GlobeNewswire | Back to overview list |